Back to search results

IM@HOME Program for People With Cancer

This study is testing a program called IM@Home, which is a 12-week virtual program focused on mind-body and fitness activities. It aims to see if this program can help improve how you feel while undergoing cancer treatment. You would join weekly online classes through Zoom. The study compares IM@Home to "enhanced usual care," which means you receive standard care plus access to pre-recorded meditation and other resources online. The main goal is to see if IM@Home can reduce fatigue (tiredness) after 12 weeks. You may be able to join if you are 18 or older, can speak English, have a good general health score (Karnofsky score 60 or greater), and have a life expectancy greater than six months. This includes people with head and neck, thoracic, gynecologic, melanoma, or breast cancer. The current status of this study is unclear.

Study design
This is an interventional study comparing two behavioral approaches: IM@Home and enhanced usual care. It plans to enroll 324 participants.
What's involved
Participants in the IM@Home group will attend virtual classes one to four times per week for 12 weeks. Fatigue levels will be measured at 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed for fatigue severity at 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05053230

A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

Active, Not Recruiting
NAAges 18+InterventionalSupportive care
Memorial Sloan Kettering Cancer Center
~324 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:IM@HomeEnhanced usual care

At a glance

Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Average Fatigue Severity from the Brief Fatigue Inventory (BFI)
Measured over 12 weeks

Conditions

Head and Neck Cancer
Head and Neck Tumor
Thoracic Tumor
Thoracic Cancer
Gynecologic Cancer
Gynecologic Tumor
Melanoma
Ovarian Cancer

Explore related trials

Ampullary CancerBreast CarcinomaCarcinoma of Endocrine GlandCholangiocarcinomaFallopian Tube CarcinomaLeukemiaLiver CarcinomaLymphomaMalignant Digestive System NeoplasmMalignant Female Reproductive System NeoplasmMalignant Genitourinary System NeoplasmMalignant Head and Neck NeoplasmMalignant Ovarian NeoplasmMalignant Testicular NeoplasmMelanomaMultiple MyelomaPancreatic CarcinomaSarcomaThoracic Neoplasm

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Karolina Bryl, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years or older
Karnofsky score 60 or greater
Life expectancy greater than six months
English speaking
Patients with a diagnosis of head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or gynecologic cancer
Actively receiving systemic oncological treatment or radiotherapy, or within 4 weeks of radiotherapy completion or primary cytoreductive surgery
Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)
Patients with a diagnosis or clinical suspicion of gynecologic malignancy who have completed definitive first line treatment (maintenance hormonal or targeted therapies are allowed)
Patients with a diagnosis of Stage III or IV lung cancer; any stage pancreatic cancer, unresectable cholangiocarcinoma, unresectable liver cancer, unresectable ampullary or peri-ampullary cancer, or other stage IV gastrointestinal cancer; stage III or IV ovarian or fallopian tube cancers or other stage IV gynecologic cancer; stage IV breast cancer; stage III testicular cancer or any stage IV genitourinary cancer; stage IV sarcoma; stage IV melanoma; stage IV endocrine cancer; lymphoma, myeloma, or Leukemia
Actively receiving oncological treatment, radiotherapy or active surveillance
Completed active cancer treatment (e.g., surgery, radiation, chemotherapy) (maintenance hormonal or targeted therapies are allowed).
Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)

Exclusion

Cognitive impairment that would preclude response to study assessments or require the use of Legally Authorized Representatives
Unwilling to accept random assignment
Concurrently enroll onto ongoing competing trials of integrative medicine interventions with symptom/toxicity as primary outcome. Note, however, patient will be allowed to enroll on other therapeutic protocols

What this trial measures

  • Average Fatigue Severity from the Brief Fatigue Inventory (BFI)12 weeks

    Primary outcome will be measured by the average fatigue severity measured by the Brief Fatigue Inventory (BFI). The BFI is a 9-item instrument designed to assess one construct of fatigue severity in cancer and non-cancer populations. Three items ask patients to rate the severity of their fatigue at its "worst," "usual," and "now" during normal waking hours, with 0 being "no fatigue" and 10 being "fatigue as bad as you can imagine." Six items assess the amount that fatigue has interfered with different aspects of the patient's life during the past 24 hours. The interference items are measured on a 0-10 scale, with 0 being "does not interfere" and 10 being "completely interferes."59 A composite fatigue severity score can be found by averaging the 9 item scores.